Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Agios Pharmaceuticals

Pharmaceutical intelligence for Agios Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Assets
2

Recent signals(2)

ClinicalJuly 23, 2026

Agios initiates trial of mitapivat in pediatric PKD patients with no transfusion history

Agios Pharmaceuticals is conducting a trial to assess mitapivat's efficacy and safety in pediatric patients with PKD who are not regularly transfused.

CompetitiveJune 24, 2026

Agios Pharmaceuticals' Mitapivat Shows Promise in Non-Transfusion-Dependent Thalassemia Study

A study is evaluating the efficacy and safety of mitapivat in patients with non-transfusion-dependent thalassemia.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 23, 2026

Agios initiates trial of mitapivat in pediatric PKD patients with no transfusion history

Agios Pharmaceuticals is conducting a trial to assess mitapivat's efficacy and safety in pediatric patients with PKD who are not regularly transfused.

Competitive activity(1)

CompetitiveJune 24, 2026

Agios Pharmaceuticals' Mitapivat Shows Promise in Non-Transfusion-Dependent Thalassemia Study

A study is evaluating the efficacy and safety of mitapivat in patients with non-transfusion-dependent thalassemia.

Assets

Agios →
Mitapivat →

Therapeutic areas

Hematology →
Pyruvate Kinase Deficiency →
Thalassemia →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.